Bioatla reports fourth quarter and full year 2022 financial results and highlights recent progress

- cleared dose-limiting toxicity (dlt) observation period with more frequent, dose-intensive regimen of cab-axl ba3011; anticipated leiomyosarcoma (lms) cohort readout in 2h23
BCAB Ratings Summary
BCAB Quant Ranking